You are here: Industry Insights > msd

News List

MSD withdraws EU application of Keytruda combination for the treatment of NSCLC pharmafile
October 31, 2017
MSD has been forced to withdraw its EU marketing application for Keytruda (pembrolizumab) in combination with pemetrexed and carboplatin as a first-line treatment for metastatic non-squamous non-small cell lung cancer (NSCLC),
MSD cuts 1,800 jobs in US operations restructure pharmafile
October 24, 2017
MSD has revealed its intention to cut 1,800 sales positions from its workforce in the US.
Trials reveal two strong vaccine candidates for Ebola pharmafile
October 17, 2017
Two clinical-stage vaccine candidates for Ebola have produced stunning results, not least because an unexpected protection emerged.
MSD pulls plug on cholesterol drug anacetrapib pharmatimes
October 13, 2017
MSD has decided to pull the plug on its late-stage cholesterol drug anacetrapib after a lacklustre performance in clinical trials.
MSD gives up on cholesterol drug, despite positive results pharmafile
October 13, 2017
MSD, known as Merck in North America, has revealed that it will not pursue a regulatory filing for its cholesterol drug, anacetrapib
Up to $20,000 available to the digital health company that solves one of the challenges proposed by worldpharmanews
September 28, 2017
MSD is looking for innovators to solve 7 health-related challenges aiming to support physician education or patient disease management.
MSD launches once-daily Isentress in the UK pharmatimes
September 27, 2017
MSD UK has launched a once-daily version of its blockbuster HIV treatment Isentress (raltegravir) in the UK.
Singapore's Pips program to give pharma sector a huge boost biospectrumasia
September 07, 2017
The industry development scheme was initiated by the Agency for Science, Technology and Research (A*Star) in partnership with the National University of Singapore
MSD’s CETP inhibitor cuts heart risk by 9 percent pharmatimes
August 31, 2017
MSD has revealed that its CETP inhibitor anacetrapib reduced the risk of major coronary events by 9 percent versus placebo in patients with cardiovascular disease already taking LDL-C lowering therapy alongside atorvastatin.
AstraZeneca unloads another drug for $400m pharmafile
August 30, 2017
AstraZeneca has had to do a serious re-think of its portfolio post-Mystic failure and it has made another move to raise cash, whilst still keeping an eye on development progress.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page